Smart Buying Tips,is defined as a small transmembrane protein of 118 amino acids

The Melan-A peptide, also widely known as Melan-A/MART-1, has emerged as a significant entity in the fields of immunology and oncology, particularly in the study and potential treatment of melanoma. This peptide is derived from the Protein Melan-A, also identified as MLANA or melanoma antigen recognized by T cells 1. The Melan-A/MART-1 protein is a differentiation antigen, meaning it is specifically expressed in melanocyte cells, which are responsible for producing pigment in the skin, and consequently, in melanoma cells. This restricted expression makes it a valuable target for therapeutic interventions.

Research indicates that the Melan-A/MART-1 protein is a small transmembrane protein of 118 amino acids. Within this protein, specific amino acid sequences function as antigenic peptides that can be recognized by the immune system, particularly by cytotoxic T lymphocytes (CTLs). One of the most extensively studied and immunodominant of these is the Melan-A(aa26-35) (EAAGIGILTV) peptide. This particular sequence is an HLA-A2-restricted T-cell epitope, meaning it is presented on the surface of cells by the HLA-A2 molecule and can elicit a T-cell response in individuals with this specific HLA type. The Melan-A (26-35) decapeptide and the Melan-A26-35 peptide analogue ELAGIGILTV are examples of such critical sequences that have been investigated for their immunogenic properties.

The significance of the Melan-A peptide lies in its role as one of the best studied human tumor-associated antigens. Its presence in both healthy melanocytes and malignant melanoma cells, coupled with its ability to trigger an immune response, positions it as a crucial target in understanding and potentially treating melanoma. Melanoma-associated peptides in general are recognized as being pivotal in cancer immunotherapy, particularly in targeting tumor-specific antigens.

The application of Melan-A/MART-1 in research spans several areas. For instance, peptide pools such as PepTivator Melan-A/MART-1 and PepMix Human Melan-A / MART-1 Overlapping Peptide Pool are utilized to stimulate T-cell responses in laboratory settings, aiding in the study of tumor immunity. These products are designed to cover the complete sequence of the Melan-A/MART-1 protein, allowing researchers to investigate various epitopes. The Melan - A/MART - 1 Peptide itself is a high-quality research product available for a wide array of chemical, biochemical, and immunological applications.

Furthermore, the Melan-A peptide has been explored in the development of therapeutic vaccines. Studies have investigated the impact of immunizations with Melan-A peptides, with observations suggesting that repeated vaccination with Melan-A peptide can lead to sustained responses of specific CD8 T cells. This is crucial for developing effective anti-melanoma strategies. The Melan-A is a melanocyte differentiation antigen recognized by cytotoxic T lymphocytes, and its potential to elicit a robust immune response is a key focus in vaccine design.

Beyond its direct use as a peptide, understanding the Melan-A/MART-1 protein itself is vital. The gene encoding this protein is MLANA, and the protein is expressed exclusively in retina, melanoma, and melanocyte cells. This exclusive expression pattern reinforces its value as a specific marker and potential therapeutic target.

The study of Melan-A peptides also involves understanding their stability and presentation. For example, research has delved into the degradation of Melan-A peptides in human serum and the mechanisms by which the final antigenic peptides are produced by proteasomes. The identification of specific peptide sequences, such as the Melan-A (26-35) decapeptide, which is an immunodominant antigen, highlights the precise nature of immune recognition.

In summary, the Melan-A peptide is a fundamental component in the study of melanoma. Its role as a specific antigen, its involvement in T-cell recognition, and its potential in immunotherapy underscore its importance. Whether as a research tool like PepTivator Melan-A/MART-1 or as a target in therapeutic strategies, the Melan-A/MART-1 continues to be a focal point in the ongoing battle against melanoma. The exploration of Melan-A peptide positive cases and understanding the nuances of Melan-A peptide melanoma interactions are essential for advancing diagnostic and therapeutic approaches.